Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Google Secures Pentagon AI Deal for Classified Projects 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
NEWTOWN, Pa., April 26, 2017 -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Dr. Ramesh Kumar, President & CEO, will present an overview at PIONEERS 2017 presented by Joseph Gunnar & Co., LLC.
Presentation Details:
Date: Tuesday, May 2, 2017
Time: 8:30 am ET
Location: Mandarin Oriental Hotel, New York City
A recording of the presentation will be available on the Investor Page of Onconova’s website and will be active for 90 days following the event.
About Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc. is a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Rigosertib, Onconova’s lead candidate, is a proprietary Phase 3 small molecule agent, which blocks cellular signaling by targeting RAS effector pathways. Using a proprietary chemistry platform, Onconova has created a pipeline of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and several active pre-clinical programs. Advanced clinical trials with our lead compound, rigosertib, are aimed at unmet medical needs of patients with MDS. For more information, please visit http://www.onconova.com.
GENERAL CONTACT: http://www.onconova.com/contact/ INVESTOR RELATIONS CONTACT: Lisa Sher, MBS Value Partners on behalf of Onconova Therapeutics [email protected] / (212) 750-5800
